Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
N/ANon-phased studies
3(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(1)
Other(2)

Detailed Status

Completed1
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A3 (100.0%)

Trials by Status

completed133%
suspended133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
completednot_applicable

The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

NCT00196040
suspendednot_applicable

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness

NCT00529945
unknownnot_applicable

Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism

NCT00196027

Clinical Trials (3)

Showing 3 of 3 trials
NCT00196040Not Applicable

The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

Completed
NCT00529945Not Applicable

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness

Suspended
NCT00196027Not Applicable

Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3